Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial

被引:50
作者
Burroughs, Lauri M. [1 ,2 ,3 ]
Nemecek, Eneida R. [4 ]
Torgerson, Troy R. [2 ,3 ]
Storer, Barry E. [1 ,2 ]
Talano, Julie-An [5 ]
Domm, Jennifer [6 ]
Giller, Roger H. [7 ]
Shimamura, Akiko [1 ,2 ,3 ]
Delaney, Colleen [1 ,2 ,3 ]
Skoda-Smith, Suzanne [2 ,3 ]
Thakar, Monica S. [5 ]
Baker, K. Scott [1 ,2 ,3 ]
Rawlings, David J. [2 ]
Englund, Janet A. [2 ,3 ]
Flowers, Mary E. D. [1 ,2 ]
Deeg, H. Joachim [1 ,2 ]
Storb, Rainer [1 ,2 ]
Woolfrey, Ann E. [1 ,2 ,3 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] Seattle Childrens Hosp, Seattle, WA USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] Vanderbilt Univ, Nashville, TN 37235 USA
[7] Childrens Hosp Colorado, Aurora, CO USA
基金
美国国家卫生研究院;
关键词
Clinical results in inherited disorders; Conditioning regimen; Allo-transplantation; Nonmalignant diseases; Reduced-intensity conditioning; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; POLYMERASE-CHAIN-REACTION; TERM-FOLLOW-UP; CHRONIC GRANULOMATOUS-DISEASE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; BUSULFAN PHARMACOKINETICS; HEMATOLOGIC MALIGNANCIES; PRIMARY IMMUNODEFICIENCY; THALASSEMIA MAJOR;
D O I
10.1016/j.bbmt.2014.08.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hematopoietic cell transplantation is an effective treatment for patients with nonmalignant diseases and for many is the only known cure. Conventional myeloablative regimens have been associated with unacceptably high early transplant-related mortality (TRM), particularly in patients with comorbid conditions. This prospective multicenter trial was designed to determine the safety and engraftment efficacy of treosulfan-based conditioning in patients with nonmalignant diseases. Thirty-one patients received HLA-matched related (n = 4) or unrelated (n = 27) grafts after conditioning with treosulfan (total dose, 42 g/m(2)), fludarabine (total dose, 150 mg/m(2)), +/- thymoglobulin (6 mg/kg; n = 22). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. All patients engrafted. Day-100 TRM was 0%. With a median follow-up of 2 years, the 2-year survival was 90%. Three patients died of GVHD, recurrent hemophagocytic lymphohistiocytosis, and a surgical complication, respectively. The cumulative incidences of grades II to IV and III to IV acute GVHD at day 100 and chronic GVHD at 2 years were 62%, 10%, and 21%, respectively. Patients who received thymoglobulin had a significantly lower incidence of grades III to IV acute GVHD (0% versus 33%; P = .005). These results indicate that the combination of treosulfan, fludarabine, and thymoglobulin is effective at establishing donor engraftment with low toxicity and improved survival in patients with nonmalignant diseases and support the need for future disease-specific clinical trials. (C) 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.
引用
收藏
页码:1996 / 2003
页数:8
相关论文
共 50 条
[41]   Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial [J].
Chiesa, Robert ;
Standing, Joseph F. ;
Winter, Robert ;
Nademi, Zohreh ;
Chu, Jan ;
Pinner, Danielle ;
Kloprogge, Frank ;
McLellen, Susan ;
Amrolia, Persis J. ;
Rao, Kanchan ;
Lucchini, Giovanna ;
Silva, Juliana ;
Ciocarlie, Oana ;
Lazareva, Arina ;
Gennery, Andrew R. ;
Doncheva, Bilyana ;
Cant, Andrew J. ;
Hambleton, Sophie ;
Flood, Terence ;
Rogerson, Elizabeth ;
Devine, Kirsty ;
Prunty, Helen ;
Heales, Simon ;
Veys, Paul ;
Slatter, Mary .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (02) :264-273
[42]   Effect of Busulfan and Treosulfan on Gonadal Function after Allogeneic Stem Cell Transplantation in Children and Adolescents with Nonmalignant Diseases Is Not Exposure-Dependent [J].
van der Stoep, M. Y. Eileen C. ;
Bense, Joell E. ;
de Kloet, Liselotte C. ;
Asmuth, Erik G. J. von ;
de Pagter, Anne P. J. ;
Hannema, Sabine E. ;
Guchelaar, Henk-Jan ;
Zwaveling, Juliette ;
Lankester, Arjan C. .
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (08) :529e1-529e5
[43]   Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide and Antithymocyte Globulin from HLA-Mismatched Related Donors for Nonmalignant Diseases [J].
Osumi, Tomoo ;
Yoshimura, Satoshi ;
Sako, Mayumi ;
Uchiyama, Toru ;
Ishikawa, Takashi ;
Kawai, Toshinao ;
Inoue, Eisuke ;
Takimoto, Tetsuya ;
Takeuchi, Ichiro ;
Yamada, Masaki ;
Sakamoto, Kenichi ;
Yoshida, Kaoru ;
Kimura, Yui ;
Matsukawa, Yukihiro ;
Matsumoto, Kana ;
Imadome, Ken-Ichi ;
Arai, Katsuhiro ;
Deguchi, Takao ;
Imai, Kohsuke ;
Yuza, Yuki ;
Matsumoto, Kimikazu ;
Onodera, Masafumi ;
Kanegane, Hirokazu ;
Tomizawa, Daisuke ;
Kato, Motohiro .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (11) :E286-E291
[44]   Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan [J].
Bernardo, Maria Ester ;
Piras, Eugenia ;
Vacca, Adriana ;
Giorgiani, Giovanna ;
Zecca, Marco ;
Bertaina, Alice ;
Pagliara, Daria ;
Contoli, Benedetta ;
Pinto, Rita Maria ;
Caocci, Giovanni ;
Mastronuzzi, Angela ;
La Nasa, Giorgio ;
Locatelli, Franco .
BLOOD, 2012, 120 (02) :473-476
[45]   Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning [J].
Casper, Jochen ;
Wolff, Daniel ;
Knauf, Wolfgang ;
Blau, Igor W. ;
Ruutu, Tapani ;
Volin, Liisa ;
Wandt, Hannes ;
Schaefer-Eckart, Kerstin ;
Holowiecki, Jerzy ;
Giebel, Sebastian ;
Aschan, Johan ;
Zander, Axel R. ;
Kroeger, Nicolaus ;
Hilgendorf, Inken ;
Baumgart, Joachim ;
Mylius, Heidrun A. ;
Pichlmeier, Uwe ;
Freund, Mathias .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3344-3351
[46]   Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [J].
Mohanan, Ezhilpavai ;
Panetta, John C. ;
Lakshmi, Kavitha M. ;
Edison, Eunice S. ;
Korula, Anu ;
Fouzia, N. A. ;
Abraham, Aby ;
Viswabandya, Auro ;
George, Biju ;
Mathews, Vikram ;
Srivastava, Alok ;
Balasubramanian, Poonkuzhali .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (03) :575-583
[47]   Reduced Intensity Conditioning and Hematopoietic Stem Cell Transplantation in Pediatric Nonmalignant Disease: A New Therapeutic Paradigm [J].
Abikoff, Cori M. ;
Cairo, Mitchell S. .
JOURNAL OF PEDIATRICS, 2014, 164 (05) :952-+
[48]   Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders [J].
Shenoy, Shalini ;
Boelens, Jaap J. .
CURRENT OPINION IN PEDIATRICS, 2015, 27 (01) :9-17
[49]   Hematopoietic stem cell transplantation for primary immunodeficiency diseases [J].
Slatter, Mary A. ;
Cant, Andrew J. .
YEAR IN HUMAN AND MEDICAL GENETICS: INBORN ERRORS OF IMMUNITY I, 2011, 1238 :122-131
[50]   Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases [J].
Faraci, Maura ;
Bagnasco, Francesca ;
Leoni, Massimiliano ;
Giardino, Stefano ;
Terranova, Paola ;
Subissi, Lorenzo ;
Di Duca, Marco ;
Di Martino, Daniela ;
Lanino, Edoardo .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) :1088-1093